NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/21/2025
Back to search
Official data from USPTO
CELYAD ONCOLOGY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
11/23/2025
Trademark type
Combined
Nice classes
5, 10, 42
Filing date
10/15/2020
Registration date
01/25/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/25/2022
Last transaction
11/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
BE
Examiner
MAHMOUDI,MARIAM AZIZ
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the dark blue stylized wording "CELYAD ONCOLOGY" appearing to the right of four translucent overlapping semi-circles forming a spiral; the bottom semi-circle is gray; the next overlapping semi-circle is dark turquoise and turquoise; the next overlapping semi-circle is dark purple, purple and pink; the last and top overlapping semi-circle is dark maroon, maroon, red and orange.
Holders and representatives
Holders
Celyad Oncology, Société anonyme
Representatives
Todd A. Denys PORZIO, BROMBERG & NEWMAN, P.C.
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; implants comprised of living tissuesfor pharmaceutical use; pharmaceutical productsproducts for the treatment of tumors and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use; compositions comprised of white blood cellsspecifically T-cells and NK-cellsfor pharmaceutical use; viral vectors in the nature of biological cultures for medical use; plasmids in the nature of DNA molecules for medical use
Class 10
Bioreactors for medical analysis; apparatus for cultureproliferation and modification of human cells for medical purposes; apparatus for cell therapy; catheters; surgical and medical instruments for use in the diagnosis and treatment of oncology and cardio-vascular diseases; medical implants consisting of artificial materials
Class 42
Scientific and technological servicesresearchanalysis and testing in the field of oncology and cardio-vascular diseases; scientific research services in the field of cell therapyoncologyimmuno-oncology and in the field of medical and surgical instruments
Publications
History of USPTO decisions and trademark events.
27 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/13/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/25/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/01/2022
FIMP
FINAL DISPOSITION PROCESSED
07/01/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/25/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/25/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/09/2021
PUBO
PUBLISHED FOR OPPOSITION
11/09/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/20/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
10/01/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/01/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
10/01/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/22/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/21/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/21/2021
RFNT
REFUSAL PROCESSED BY IB
04/13/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/24/2021
RFRR
REFUSAL PROCESSED BY MPU
03/24/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/20/2021
CNRT
NON-FINAL ACTION WRITTEN
03/19/2021
DOCK
ASSIGNED TO EXAMINER
03/16/2021
MAFR
APPLICATION FILING RECEIPT MAILED
12/04/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/30/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/26/2020
Continuous trademark protection
Get notified about every new filing that threatens CELYAD ONCOLOGY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.